Company intelligence / Profile preview

SPH-BIOCAD

Hong Kong SAR, China

Ownership: Private
Development stage: Other

Overview

The company has multiple products in development, with two products (PD-1 and IL-17A antibodies) in Phase 3 clinical trials and others in IND application stage. The PD-1 monoclonal antibody (Prolgolimab) is being tested for cervical cancer and non-small cell lung cancer indications, while the IL-17A antibody (Netakimab) has been launched in Russia and is being tested for psoriasis and ankylosing spondylitis indications.

Therapeutic areas: OncologyDermatologyRheumatology
Modalities: Monoclonal antibodiesBiosimilars
Industry: Biotech

Partnerships

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH)Biocad

Beyond the preview

Go deeper on SPH-BIOCAD.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPH-BIOCAD.

Explore the full profile